177Lu-PSMA-I&T
- Generic Name
- 177Lu-PSMA-I&T
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
Phase 3
Active, not recruiting
- Conditions
- Metastasis From Malignant Tumor of Prostate
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Curium US LLC
- Target Recruit Count
- 439
- Registration Number
- NCT05204927
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇪🇸Hospital Regional Universitario de Malaga, Málaga, Spain
Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer
Phase 1
Suspended
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 48
- Registration Number
- NCT04886986
- Locations
- 🇺🇸
Brooklyn Methodist Hospital - New York Presbyterian, Brooklyn, New York, United States
🇺🇸Weill Cornell Medicine New York Presbyterian, New York, New York, United States
177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2019-12-06
- Target Recruit Count
- 30
- Registration Number
- NCT04188587
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath